Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Foamix Pharma Ord (FOMX)

Foamix Pharma Ord (FOMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 272,192
  • Shares Outstanding, K 61,582
  • Annual Sales, $ 3,600 K
  • Annual Income, $ -74,160 K
  • 60-Month Beta 1.75
  • Price/Sales 206.34
  • Price/Cash Flow N/A
  • Price/Book 4.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.74 +18.18%
on 01/30/20
4.84 -8.68%
on 01/16/20
+0.14 (+3.27%)
since 01/14/20
3-Month
2.74 +61.02%
on 12/11/19
4.84 -8.68%
on 01/16/20
+0.98 (+28.49%)
since 11/14/19
52-Week
1.97 +124.37%
on 07/26/19
4.84 -8.68%
on 01/16/20
+0.88 (+24.86%)
since 02/14/19

Most Recent Stories

More News
Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder...

FOMX : 4.42 (+3.51%)
MNLO : 5.07 (+1.60%)
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies...

FOMX : 4.42 (+3.51%)
Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies...

FOMX : 4.42 (+3.51%)
Actinic (Solar) Keratosis Treatment Market Analysis with Lucrative Strategies and Irreplaceable Counsel by 2025

The Big Market Research has recently added a new survey report to their vivid and dynamic database. They have formulated this report by taking into consideration all the key aspects that tend to have an...

ATNX : 14.78 (-0.81%)
FOMX : 4.42 (+3.51%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 1.0581 (-2.93%)
Actinic (Solar) Keratosis Treatment Market Development Study: Big changes will have a big Impact

HTF MI recently introduced latest version Actinic (Solar) Keratosis Treatment Market Study 2019. It covered product Scope, Market Share, Size, Revenue, Opportunities, Growth Rate, Sales Growth, Demand,...

FOMX : 4.42 (+3.51%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 1.0581 (-2.93%)
Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC ("OrbiMed"), a significant shareholder of the Company,...

FOMX : 4.42 (+3.51%)
OrbiMed Supports the Proposed Foamix Pharmaceuticals Ltd. And Menlo Therapeutics Inc. Merger

OrbiMed Advisors LLC ("OrbiMed"), on behalf of its clients, has evaluated the Joint Proxy Statement/Prospectus for the proposed merger of Foamix Pharmaceuticals Ltd. ("Foamix") and Menlo Therapeutics Inc....

FOMX : 4.42 (+3.51%)
Actinic (Solar) Keratosis Treatment Market to witness major growth in coming years

Ameco Research Presents “” New Document to its Studies Database. The Report Contain 116 Pages With Detailed Analysis.

ATNX : 14.78 (-0.81%)
FOMX : 4.42 (+3.51%)
NVS : 97.63 (-0.14%)
VRX.TO : 30.80 (-3.33%)
VEGPF : 1.0581 (-2.93%)
Foamix Announces AMZEEQ(TM) (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced a coverage update for its novel AMZEEQ(TM) (minocycline) topical foam, 4%. AMZEEQ...

FOMX : 4.42 (+3.51%)
Foamix Announces AMZEEQ(TM) (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that its novel AMZEEQ(TM) (minocycline) topical foam, 4% will be available on...

FOMX : 4.42 (+3.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FOMX with:

Business Summary

Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe...

See More

Key Turning Points

2nd Resistance Point 4.62
1st Resistance Point 4.52
Last Price 4.42
1st Support Level 4.25
2nd Support Level 4.08

See More

52-Week High 4.84
Last Price 4.42
Fibonacci 61.8% 3.74
Fibonacci 50% 3.41
Fibonacci 38.2% 3.07
52-Week Low 1.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar